ZIVO Bioscience Advances Innovative Coccidiosis Solutions

Exciting Developments at ZIVO Bioscience

BLOOMFIELD HILLS, Mich. — Zivo Bioscience, Inc. (OTCQB: ZIVO), a trailblazer in biotechnological and agricultural research, is making significant headway with its innovative product designed to combat coccidiosis in broiler chickens. The company has recently updated stakeholders about its ongoing discussions concerning licensing opportunities for this vital treatment.

Progress in Licensing Negotiations

Following promising outcomes from a comprehensive 42-day coccidiosis study, ZIVO has been in active talks with several prominent global animal health companies, considering an exclusive licensing agreement. These discussions are ongoing as potential licensees complete their due diligence, which includes meticulous evaluations of the technical, patent, and business aspects of ZIVO's product.

Looking Ahead: Formal Agreements

If these due diligence processes conclude satisfactorily, ZIVO plans to enter formal negotiations soon, aiming to finalize a licensing agreement within the first quarter of the next year. The company is keen to secure terms that involve upfront payments, milestone payments aligned with commercialization achievements, and ongoing royalties derived from product sales.

Vision for Long-Term Success

John B. Payne, Chairman and CEO of ZIVO Biosciences, expressed confidence in their strategy. "We aim for an agreement that complements our commercialization plan and provides enduring value for our shareholders. The interest shown by potential partners has been encouraging, and we are excited about our product's potential impact both as a standalone solution and in enhancing existing veterinary treatments like ionophores and vaccines," he noted.

Further Developments in Poultry Health

Additionally, ZIVO has announced intentions to progress their efforts relating to a product candidate focused on Low Pathogenicity Avian Influenza (LPAI) control in poultry. With fresh studies planned at the University of Delaware, the company aims to refine dosage and formulation to maximize efficacy and market readiness.

Understanding Coccidiosis

Coccidiosis is a serious protozoal disease affecting poultry, leading to severe consequences such as diarrhea, reduced weight, and heightened mortality rates. This ailment represents a massive economic burden for the global poultry sector, racking up costs that exceed $15 billion annually. The industry primarily relies on outdated antibiotic and ionophore treatments, which are increasingly being criticized for encouraging drug resistance.

In the recent years, the poultry industry has spent about $1.1 billion on managing coccidiosis, and this figure is expected to rise to $1.5 billion by 2029. ZIVO’s innovation comes at a crucial time when the industry is seeking safer alternatives.

The Commitment of ZIVO Bioscience

ZIVO Bioscience, Inc. takes pride in its comprehensive intellectual property portfolio, showcasing proprietary algal strains and biologically active molecules for applications that span human and animal health. The focus on research and development underscores the company's dedication to solving pressing challenges in poultry health.

For those interested in exploring the innovative solutions offered by ZIVO, the company encourages visiting their website for detailed information on their research initiatives and product offerings.

Frequently Asked Questions

What is coccidiosis and why is it significant?

Coccidiosis is a protozoal infection in poultry that causes severe health issues and represents a significant financial burden for the poultry industry.

What steps is ZIVO taking towards commercialization?

ZIVO is actively negotiating licensing agreements with global animal health companies, focusing on securing terms that support product sales.

How does ZIVO’s product differ from existing treatments?

The product under development by ZIVO promises to enhance the effectiveness of conventional treatments while providing a safer alternative to outdated options.

What future studies are planned by ZIVO?

ZIVO is planning further studies at the University of Delaware to optimize their product for controlling LPAI in poultry.

Where can I find more information about ZIVO Bioscience?

More details about their research and product offerings are available on the ZIVO Bioscience website.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.